logo
Women are ageing into silence. India can't afford to ignore menopause

Women are ageing into silence. India can't afford to ignore menopause

Time of India6 hours ago

Every woman who lives long enough will experience menopause — the end of her ovarian function. Yet in India, this transition remains shrouded in taboo, misinformation, and medical neglect.
Tired of too many ads? go ad free now
While global awareness of women's midlife health gains momentum, India lags dangerously behind. Most Indian women begin menopause in their mid-40s — years earlier than women in developed nations — and often navigate this transition without medical guidance, reliable information, or therapeutic support. If India is to secure a healthier and more economically stable future, we must bring menopause out of the shadows and integrate it into national health policy.
A Silent Health Crisis
Menopause affects half the population, yet receives a fraction of the attention devoted to other life stages. In India, the absence of public dialogue, policy recognition, and accessible clinical care has created widespread suffering behind closed doors. This silence isn't merely social — it's systemic, embedded in India's healthcare infrastructure and medical education.
Consider this: while pregnancy and childbirth receive substantial medical attention and government support, the phase that follows — when women spend potentially 30-40 years of their lives post-menopause — remains largely ignored.
This medical blind spot has serious consequences for women's health, economic productivity, and quality of life.
South Asian Disadvantage
Indian women face a unique challenge. Research shows that South Asian women typically reach menopause between ages 45-47, compared to the global average of 50-52. This earlier onset stems from multiple factors: nutritional deficiencies, early pregnancies, lower body mass index, and limited access to preventive healthcare throughout their reproductive years.
Tired of too many ads? go ad free now
The implications are profound. Indian women spend more years in the post-menopausal phase, facing elevated risks for cardiovascular disease, osteoporosis, diabetes, and cognitive decline. A recent FP Analytics report reveals that Central and Southern Asia will see the greatest increase globally in women entering menopause by 2050. By 2030, nearly half a billion women worldwide aged 45-55 will be in this transition, with India contributing significantly to these numbers.
Without adequate medical infrastructure and education, this demographic shift threatens to overwhelm India's healthcare system.
Medical Gaps and Missed Opportunities
Cultural discomfort around menopause compounds clinical shortcomings. Many Indian doctors remain hesitant to prescribe hormone replacement therapy (HRT), despite it being first-line treatment internationally. Women frequently report being dismissed when presenting symptoms like brain fog, insomnia, anxiety, or joint pain — symptoms often attributed to 'normal aging' rather than treatable menopausal changes.
Dr.
, a gynecologist at AIIMS Delhi, notes: 'We see women suffering in silence because they don't know these symptoms are connected to menopause. And when they do seek help, many practitioners lack the training to provide appropriate care.'
The medical curriculum in India dedicates minimal time to menopause management, leaving healthcare providers ill-equipped to address this critical life stage. This knowledge gap perpetuates a cycle of inadequate care and continued suffering.
The Hidden Economic Cost
While India lacks comprehensive data on menopause-related economic losses, international studies paint a concerning picture. In the UK, menopause-related productivity losses cost the economy billions annually through absenteeism, reduced performance, and early retirement. Given India's massive female workforce and rising life expectancy, similar economic impacts are inevitable without intervention.
Consider the ripple effects: when women struggle with untreated menopausal symptoms, it affects not just their careers but their families' economic stability. As more women enter the workforce, ignoring their midlife health needs becomes economically unsustainable.
From Exception to Epidemic: The Great Transition
For most of human history, menopause was a biological rarity. A century ago, when Indian women lived an average of 25-35 years, most died before their ovaries ceased functioning.
Today, with life expectancy reaching 71 years for women, India has crossed a critical threshold: menopause has transformed from the exception to the norm.
Consider the mathematics of this shift. With menopause typically occurring in the late 40s for Indian women, and life expectancy now extending into the 70s, the majority of Indian women will spend 25-30 years of their lives in a post-menopausal state. What was once experienced by a small fraction of the population now affects hundreds of millions of women.
We have successfully extended human lifespan, but we have not extended ovarian function to match.
This demographic reality demands a fundamental rethinking of women's health. Every other vital organ system receives extensive medical attention when it begins to fail. We develop treatments for heart disease, interventions for kidney dysfunction, and therapies for liver disorders. Yet when it comes to ovarian failure — which affects metabolism, immune function, cardiovascular health, bone density, and cognitive performance — we simply accept it as inevitable.
Beyond Acceptance: Reimagining Ovarian Health
But what if menopause didn't have to be inevitable? What if, just like we've learned to support other aging organs, we could extend ovarian function throughout a woman's lifespan?
When most people think about the ovary, they think about babies. When they think about menopause, they think 'hot flashes.' However, groundbreaking research in the field of Ovarian Health has demonstrated that the ovary is much more than simply a 'reproductive organ.'
The consequences of ovarian dysfunction — whether in early life through conditions like PCOS (affecting 15% of women globally) or in midlife through menopause — help explain why women are sick for 25% more of their lives than men.
The ovary serves as the 'central command' of a woman's health and vitality, critical to every major system and function of her body. This makes menopause the single biggest accelerant of unhealthy aging for women, including the onset of heart disease, stroke, obesity, diabetes, autoimmune disorders, osteoporosis, and cognitive decline.
My research team at Celmatix Therapeutics, supported by a prestigious ARPA-H SPARK award from the U.S. government in 2024, has been pioneering breakthrough therapeutics designed to extend ovarian function throughout the modern lifespan.
This isn't about indefinitely extending fertility. Eggs age on their own biological timeline regardless of ovarian health. Instead, our work focuses on therapeutically regulating ovarian folliculogenesis through drugs that target Anti-Mullerian Hormone (AMH).
Women are born with a finite number of ovarian follicles, and AMH acts as molecular brakes, keeping this reserve from depleting too quickly. By strategically modulating these brakes during the years when women aren't trying to conceive, we can extend ovarian function throughout the lifespan.
The implications are profound. Rather than accepting that the timing of menopause is fixed, we're working toward a future where it becomes a choice — where women can anticipate living healthy, active lives with fully functioning ovaries well into their nineties.
They won't just survive past middle age; they will thrive.
A Blueprint for Change
Addressing India's menopause crisis requires coordinated action across multiple sectors:
Healthcare System Reform:
Integrate menopause care into existing programs like Ayushman Bharat and the National Health Mission. Establish specialized menopause clinics in urban centers and train primary healthcare workers to recognize and manage menopausal symptoms.
Medical Education Overhaul:
Mandate comprehensive menopause training in medical curricula. Develop continuing education programs for practicing physicians, particularly in gynecology and family medicine.
Public Awareness Campaigns:
Launch national initiatives to normalize menopause discussions. Use regional languages and culturally appropriate messaging to reach diverse populations. Leverage popular media and community health workers to spread awareness.
Workplace Adaptation:
Encourage employers to implement menopause-friendly policies, including flexible work arrangements, adequate healthcare coverage, and awareness programs for managers and colleagues.
Research Investment:
Fund studies specific to Indian women's menopause experiences, considering regional variations in diet, lifestyle, and genetics. This research should inform evidence-based treatment protocols.
A global imperative
India's opportunity to lead in this space is significant. While recent years have seen increased awareness and media coverage of menopause, there's a risk of falling into what I call the 'empowerment' narrative trap — suggesting women should feel proud of being menopausal rather than addressing the catastrophic health impacts. We don't celebrate osteoarthritis, tooth decay, cognitive decline, or heart failure, and we shouldn't celebrate ovarian failure either.
The economic implications are staggering. Women comprise 80% of home and professional healthcare providers globally and play an increasingly vital role in the workforce. With more menopausal women in the workforce than ever before, the consequences of untreated ovarian dysfunction ripple through entire economies. When women thrive through better ovarian health, societies benefit immeasurably.
For India specifically, this represents both a challenge and an unprecedented opportunity.
As the country with one of the world's largest populations of women entering menopause, India could pioneer new models of ovarian health that benefit not just its own citizens, but women globally. The question isn't whether the country can afford to invest in this research — it's whether India can afford not to.
The path forward
As India's population ages and women's life expectancy increases, menopause will affect an unprecedented number of women.
We can either address this proactively or face the consequences of continued neglect. The choice reflects our commitment to women's health and economic participation.
Other countries offer valuable lessons. Australia's National Menopause Guidelines and the UK's workplace menopause policies demonstrate what's possible with political will and systematic change. India has the opportunity to leapfrog traditional approaches and create innovative solutions suited to our unique context.
The second half of women's lives matters. By investing in menopause care today, India can unlock healthier, more productive futures for millions of women — and strengthen our society as a whole. The time for silence has passed; the time for action is now.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Atal Institute of Medical Super Specialties to be Himachal's first to perform robotic surgery
Atal Institute of Medical Super Specialties to be Himachal's first to perform robotic surgery

Indian Express

time36 minutes ago

  • Indian Express

Atal Institute of Medical Super Specialties to be Himachal's first to perform robotic surgery

The Atal Institute of Medical Super Specialities (AIMSS) at Chamiyana in Shimla is set to become the first medical institute in Himachal Pradesh to introduce surgeries using cutting-edge robotic technology. A state-of-the-art surgical robot — procured at a cost of Rs 28 crore on the lines of AIIMS Delhi — has already arrived at the institute. The installation process is expected to be completed by July, following which robotic-assisted surgeries will commence. Dr Brij Lal, principal, AIMSS Chamiyana, said that robotic surgery will offer significant benefits to both patients and doctors. 'Robotic procedures require only small incisions, resulting in minimal blood loss, reduced need for transfusions, and faster recovery for patients. They experience less pain and are discharged sooner,' he said. Doctors too will gain from the technology, as robotic systems enhance surgical precision and control. 'Surgeons experience less fatigue, even during prolonged operations, enabling them to perform more procedures efficiently. The technology provides a clear, magnified 3D view of narrow and complex areas within the body, significantly reducing the risk of errors,' Lal added. Meanwhile, a government spokesperson said in a bid to further strengthen healthcare infrastructure in Himachal Pradesh, Chief Minister Sukhvinder Singh Sukhu is set to visit Dr Rajendra Prasad Government Medical College (RPGMC), Tanda. As part of the visit, a detailed presentation will be made on the ongoing and proposed improvements in medical services and infrastructure at the institute. 'The CM will also engage in an interactive session with the faculty members to gather feedback and suggestions, focusing on enhancing healthcare delivery at this key medical institution,' the spokesperson added.

Sunscreen Isn't Seasonal—It's Essential for Year-Round Skin Health
Sunscreen Isn't Seasonal—It's Essential for Year-Round Skin Health

Time of India

time3 hours ago

  • Time of India

Sunscreen Isn't Seasonal—It's Essential for Year-Round Skin Health

Many people still see sunscreen as a summer-only staple, reserved for beach days or tropical vacations. But the truth is, UV rays are present all year, regardless of season or weather. UVA rays responsible for premature aging and skin cancer penetrate clouds, windows, and even car windshields. Up to 80% of UV radiation can pass through overcast skies, and reflective surfaces like snow, sand, and water can double your exposure. Damage from this invisible assault is cumulative, permanent, and often goes unnoticed until it's too late. Aniruddha Ghosh,Dermatologist, MD - Dermatology , Venereology & Leprosy, Ghosh Clinic, Kolkata Over 80% of our sun exposure is incidental, picked up during everyday tasks like walking to work, driving, or sitting near a window. Skin aging —wrinkles, pigmentation, loss of elasticity is driven more by UV damage than by time. And while melanin offers some natural protection, it doesn't make darker skin immune to UV-related damage or skin cancer. Jyoti Agarkar, Dermatologist, Glamore Clinic, Mumbai Skipping sunscreen in winter or on cloudy days allows invisible damage to accumulate. This can lead to not only cosmetic concerns but also serious health risks. In fact, most skin cancers are directly linked to preventable UV exposure. Kathakali Chatarjee, Dermatologist, MD - MD- Skin & VD, Kolkata Sunscreen isn't just a beauty product; it's a basic health habit—akin to brushing your teeth or wearing a seatbelt. Daily SPF use helps protect your skin's appearance and integrity, supports long-term skin health, and reduces cancer risk. Nidhi Jindal, Dermatologist, MBBS, MD - Dermatology, Oliva Skin & Hair Clinic, Kolkata Ultimately, using sunscreen daily isn't just skincare—it's self-care. It's a small daily step toward protecting your future self. By making it a habit, you help halt the damage that accumulates silently from UV exposure over time. So whether it's sunny, cloudy, or cold, remember: sunscreen is not seasonal. It's essential. Sandip Lathiya, Dermatologist, MD - Dermatology , Venereology & Leprosy, Dr. Lathiya'S Skin Hair & Laser clinic, Bhavnagar, Gujarat The HALT THE DAMAGE, FACE THE WORLD campaign by LUPIN addresses the growing threat of sun damage among the Indian population. With rising UV exposure and rising pollution levels, contributing to Skin Damage by causing issues such as Pigmentation, Breakouts, and Premature aging. The campaign urges early education on the importance of Daily Sun Protection, and Proactive Skincare to Halt the Skin Damage, by promoting awareness and encouraging consistent use of dermatologist-backed solutions, this initiative empowers individuals to take control of their skin health before the damage becomes permanent. It's a vital step toward building a sun-smart generation that faces the world with confidence and care. Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.

Genomic testing sees sharp uptake in India, now growing beyond metros
Genomic testing sees sharp uptake in India, now growing beyond metros

Business Standard

time4 hours ago

  • Business Standard

Genomic testing sees sharp uptake in India, now growing beyond metros

With 18 per cent CAGR, India's genomic diagnostics market is expanding into Tier 2 and 3 cities as affordability, cancer screening, and personalised care fuel adoption Anjali Singh Mumbai Demand for genomic testing in India has surged significantly over the past two to three years, fuelled by growing clinical awareness, rapid technological advancements and the rising adoption of personalised medicine. From being a niche service concentrated in major metros, genomic diagnostics are now expanding into Tier 2 and Tier 3 cities, reshaping the landscape of preventive and precision healthcare. The Indian genomic diagnostics market is valued at $550 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 18 per cent, reaching $2,066.31 million by 2030, according to industry estimates. Key drivers include wider physician adoption, declining test prices, improved accessibility and a shift in consumer behaviour towards proactive and personalised healthcare. Diagnostic majors such as Agilus Diagnostics, Metropolis Healthcare, Dr Lal PathLabs, Mahajan Imaging and Labs, and Redcliffe Labs report double-digit growth in the segment. While metros like Mumbai, Bengaluru and Delhi still contribute the lion's share, growing awareness and infrastructure in cities like Lucknow, Bhubaneswar, Pune, Kochi and Surat are driving demand beyond urban hubs. Test affordability has improved substantially. Prices for routine genomic tests—like BRCA1/2 (used to analyse a person's DNA to identify mutations in genes that increase the risk of breast and ovarian cancer) and NIPT (non-invasive prenatal testing, a blood test performed on pregnant women to assess the risk of certain genetic conditions in the foetus)—have come down by 30–40 per cent, now ranging between Rs 5,000 and Rs 20,000, depending on complexity. While advanced oncology panels and exome sequencing can still cost up to Rs 2 lakh, widespread adoption of high-throughput platforms and in-house test development has made even complex testing more accessible. Experts believe that although demand for genomic testing is rising across multiple segments, increasing cancer incidence and a countrywide focus on cancer detection and reproductive health have been key growth drivers. 'The rapid increase in demand for cancer tests, along with paediatric and reproductive health applications like prenatal testing and carrier testing, are major contributing factors driving growth in genetic testing. The country is also witnessing a rise in testing for rare genetic diseases, driven by India's huge genetic diversity,' said Nilaya Varma, group chief executive officer and co-founder, Primus Partners. 'Genomic testing now contributes 5–7 per cent of our total diagnostics revenue, up from under 2 per cent three years ago,' said Anand K, managing director and chief executive officer, Agilus Diagnostics. Redcliffe Labs pegs this number even higher, at 30–40 per cent, with consistent 20 per cent year-on-year growth in test volumes. 'We've seen a dramatic rise in genomic testing demand over the past five years, especially in oncology, rare diseases and reproductive health. What's encouraging is that Tier 2 and 3 cities like Lucknow, Bhubaneswar and Coimbatore are now actively adopting these tests,' said Himani Pandey, lab head – genomics, Redcliffe Labs. Metropolis Healthcare, which entered the genomics space three years ago, has seen over 50 per cent revenue growth in the segment and plans further expansion through investments in bioinformatics and next-generation sequencing (NGS) platforms. 'We've seen over 50 per cent revenue growth in genomics since our entry into the space three years ago. Genomic testing is increasingly being integrated into routine health check-ups, cancer diagnostics, rare disease screening and personalised treatment planning. We are investing heavily in bioinformatics and NGS platforms to scale further,' said Kirti Chadha, chief scientific and innovation officer, Metropolis Healthcare. Similarly, Dr Lal PathLabs, through its genomics division Genevolve, has launched over 500 tests covering oncogenomics, neurogenomics, rare disease panels and reproductive health. 'With Illumina's NovaSeq X platform at our national reference lab and a focused genomics sales team, we're bringing cutting-edge testing to both metros and smaller towns,' said Shankha Banerjee, chief executive officer, Dr Lal PathLabs. While margins on genomic tests can vary—and in many cases remain lower than routine diagnostics due to high input costs and low volumes—players see genomics as a long-term strategic bet. 'It's not just about margins—it's about clinical value and helping doctors make better treatment decisions,' said Shelly Mahajan, lab director at Mahajan Imaging. A common thread across players is the push for in-house development and Indian population–specific panels, often coupled with global partnerships for specialised tests. Most labs are also investing in AI-driven bioinformatics, advanced molecular labs and automation to enhance scalability. Yet, challenges remain. Despite cost reductions, insurance coverage for genomic tests in India is still extremely limited, creating affordability barriers for patients in lower-income segments. Industry leaders stress that broader insurance inclusion could accelerate adoption, particularly for cancer, rare diseases and reproductive health-related tests. Nonetheless, the momentum is clear: Genomic testing is no longer a fringe offering. With its ability to provide deep molecular insights for early diagnosis, targeted therapy and risk prediction, it is fast becoming a core pillar in India's diagnostics growth strategy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store